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ABSTRAK 
PERBANDINGAN ANTARA KEBERKESANAN NEOSTIGMINE DAN 
SUGAMMADEX DALAM PEMBALIKAN SEMULA KESAN RELAXAN 
OTOT DAN SARAF DISEBABKAN ROCURONIUM DALAM KALANGAN 
PESAKIT KANAK-KANAK 
 
Pengenalan : Pesakit yang diberikan bius penuh (bius am) dengan ubat relaxan 
kerap kali diberikan ubat untuk mengembalikan fungsi otot dan saraf pada akhir 
pembedahan sebelum pesakit diekstubasi. Ubat neostigmine yang telah digunakan 
bertahun-tahun dalam amalan seharian anestesia menyebabkan kesan sampingan 
yang kurang menyenangkan pada pesakit. Sugammadex, ubat baru yang telah 
diperkenalkan dalam dekad yang lepas, menentang secara khusus tindakan ubat 
relaxan ‘non-depolarizing neuromuscular blocking agents (NMBA)’ kumpulan 
‘aminosteroidal’. 
 
Objektif : Tujuan kajian ini adalah untuk membandingkan masa yang diambil untuk 
mengembalikan fungsi otot dan saraf, kestabilan hemodinamik dan kesan sampingan 
antara dua agen ini dalam menentang tindakan rocuronium (sejenis ubat relaxan 
NMBA kumpulan ‘aminosteroidal’) dalam populasi kanak-kanak. 
 
Metodologi : Kajian ini berbentuk prospektif, ‘double-blinded’, ‘randomized 
controlled trial’ melibatkan 80 pesakit kanak-kanak berumur 2-12 tahun, yang 
xvii 
 
dijadualkan untuk menjalani pembedahan dengan pembiusan am (bius penuh), 
menggunakan ubat relaxan rocuronium. Pesakit-pesakit ini telah dibahagikan secara 
rawak kepada 2 kumpulan, di mana 40 pesakit menerima ubat neostigmine dan 40 
pesakit menerima ubat sugammadex untuk membalikkan semula kesan relaxan 
rocuronium ke atas otot dan saraf. Semua pesakit diberikan gas sedutan bius 
sevoflurane, kemudian diletakkan branula saiz berpatutan. 2mcg/kg fentanyl 
diberikan dan TOF Watch Sx dipasangkan di tangan pesakit  untuk mengukur 
tindakbalas ibu jari (otot adductor policis) melalui saraf ulnar. Seterusnya, TOF 
Watch Sx dikalibrasi dan bacaan diambil. 0.6mg/kg rocuronium diberikan dan 
intubasi trakea dilalukan apabila TOF kurang dari 1. Bacaan TOF dikekalkan 2 
hingga 3 sepanjang pembedahan dengan memberikan 0.2mg/kg rocuronium jika 
TOF lebih dari 3. Bacaan parameter hemodinamik sebelum dan selepas pemberian 
neostigmine atau sugammadex diambil dan dicatatkan. Masa yang diambil untuk 
mencapai bacaan nisbah TOF 0.9 dari bacaan TOF 2 atau 3 setelah pesakit diberikan 
neostigmine atau sugammadex dicatatkan. Sebarang komplikasi yang dialami oleh 
pesakit didokumenkan. 
 
Keputusan : Masa yang diambil untuk pembalikan semula fungsi otot dan saraf dari 
TOF 2 atau 3 ke nisbah TOF 0.9 lebih lama dalam kumpulan pesakit yang menerima 
ubat neostigmine dengan min masa 501.58 saat berbanding dengan kumpulan pesakit 
yang menerima sugammadex iaitu 84.45 saat. Min perbezaan antara dua kumpulan 
ini ialah 417.13 saat. Perbezaan antara 2 kumpulan ini adalah ketara dari segi statistik, 
dengan p<0.05. Perubahan parameter hemodinamik tekanan darah (sistolik, diastolik 
dan min tekanan arterial)  adalah ketara dalam kedua-dua kumpulan jika 
dibandingkan sebelum dan selepas pemberian agen reversi. Namun begitu, min 
xviii 
 
perbezaan parameter hemodinamik dalam kumpulan sugammadex lebih rendah, iaitu 
-2.38 hingga -2.93 berbanding kumpulan neostigmine iaitu -4.85 hingga -6.80. Min 
degupan jantung sebelum dan selepas pemberian agen menunjukkan perubahan 
ketara dalam kumpulan neostigmine, tetapi tidak ketara dalam kumpulan 
sugammadex. Peratus kesan sampingan yang dialami oleh pesakit adalah lebih tinggi 
dalam kumpulan neostigmine iaitu 17.5% (7 pesakit) mengalami mual dan muntah 
manakala 2.5% (1 pesakit) berpeluh. Tiada kesan sampingan yang dilihat dalam 
kumpulan pesakit yang menerima sugammadex. 
 
Kesimpulan : Masa pembalikan fungsi otot dan saraf (dari TOF 2 atau 3 ke nisbah 
TOF 0.9) adalah jauh lebih singkat dalam kumpulan sugammadex berbanding 
kumpulan neostigmine. Sugammadex juga mempunyai profil hemodinamik yang 
lebih stabil berbanding neostigmine apabila digunakan untuk menentang kesan 
relaxan otot dan saraf ubat rocuronium. Sugammadex didapati mempunyai kurang 
kesan sampingan jika dibandingkan dengan neostigmine. 
 
Carian : Rocuronium, Neostigmine, Sugammadex, TOF, Kanak-kanak 
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ABSTRACT 
COMPARISON BETWEEN THE EFFICACY OF NEOSTIGMINE VERSUS 
SUGAMMADEX REVERSAL OF ROCURONIUM INDUCED 
NEUROMUSCULAR BLOCKADE IN PAEDIATRIC PATIENTS 
 
Introduction : A reversal agent is commonly given to improve neuromuscular 
function after intra-operative administration of non-depolarizing neuromuscular 
blocking agents. The administration of conventional reversal agent neostigmine is 
associated with many undesirable side effects. For almost a decade, a new novel drug 
sugammadex has been used to specifically antagonize the effect of aminosteroidal 
neuromuscular blocking agents.  
 
Objectives : The aim of this study is to compare the recovery time, haemodynamic 
stability and complications between these 2 reversal agents in antagonizing the 
effects of rocuronium in the paediatric population.   
 
Methodology :  This was a prospective, double-blinded, randomized controlled trial 
involving 80 paediatric patients aged between 2-12 years old scheduled for surgery 
under general anaesthesia requiring rocuronium induced neuromuscular blockade. 
They were randomized equally into two groups, 40 patients each group for reversal 
with neostigmine or reversal with sugammadex. All patients were induced with 
sevoflurane, intravenous access obtained, then 2mcg/kg of fentanyl was administered. 
xx 
 
Neuromuscular function monitoring (acceleromyography) of the adductor pollicis 
muscle was done using train-of-four (TOF) method. TOF-Watch Sx was placed 
along the ulnar groove of the hand and calibrated. After a baseline TOF reading was 
taken, and 0.6mg/kg of rocuronium was given. Patients were intubated once TOF 
count was less than 1. TOF was monitored and maintained at count of 2-3 throughout 
the surgery by administering 0.2mg/kg of rocuronium once TOF count was more 
than 3. The haemodynamic parameters pre-reversal and post-reversal was 
documented. The neuromuscular recovery time, from reversal administration at TOF 
count 2 or 3 to TOF ratio 0.9 was documented. Any complications observed post-
extubation were documented.   
 
Results : The neuromuscular recovery time from TOF count 2 or 3 to TOF ratio 0.9 
post-reversal was significantly higher in the neostigmine group, with a mean of 
501.58 seconds as compared to only 84.45 seconds in the sugammadex group. The 
mean difference was 417.13 seconds. This difference was statistically significant 
evidenced by p<0.05. There were also significant changes in the means of systolic 
blood pressure, diastolic blood pressure and mean arterial pressure pre-reversal and 
post-reversal in both groups. However the mean differences were much lower in the 
sugammadex group, ranging from -2.38 to -2.93 as compared to the neostigmine 
group, which were from -4.85 to -6.80. The mean heart rate pre-reversal and post-
reversal showed significant changes in the neostigmine group, but the changes were 
not significant in the sugammadex group. The incidence of complications post-
reversal was higher in the neostigmine group with 17.5% (7 patients) post-operative 
nausea vomiting and 2.5%  (1 patient) sweating. There were no complications noted 
in the sugammadex group. 
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Conclusion : Sugammadex has a significantly shorter recovery time (from TOF 
count of 2 or 3 to TOF ratio of more than 0.9) as compared to neostigmine. 
Sugammadex has a more stable haemodynamic profile as compared to neostigmine 
when used to reverse rocuronium induced neuromuscular blockade in paediatric 
patients. Sugammadex causes less complications or side effects when used in 
paediatric patients as a reversal for rocuronium induced neuromuscular bloackade. 
 
Keywords : Rocuronium, Neostigmine, Sugammadex, TOF, Paediatrics 
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CHAPTER 1 : INTRODUCTION 
 
Neuromuscular blocking agents (NMBAs) are frequently used during general 
anaesthesia to facilitate tracheal intubation, artificial ventilation, and adequate 
muscle relaxation for surgical procedures. Reversal agents are often administered at 
the end of surgery when there is evidence of return of neuromuscular function, to 
accelerate recovery from neuromuscular blockade and to prevent post-operative 
residual curarization (Plaud et al., 2009). 
 
Following the use of neuromuscular blocking agents for the various benefits 
it imposes during general anaesthesia, concerns have also been raised about the risks 
of postoperative residual neuromuscular blockade which may be associated with 
airway obstruction, pulmonary complications, hypoxia and increased mortality 
(Khuenl-Brady et al., 2010). There are several ways to reduce the risk of developing 
residual block when using NMBAs. One approach is to wait for spontaneous 
recovery of neuromuscular block combined with clinical evaluation of recovery of 
neuromuscular function. However clinical tests such as leg lift, head lift or hand grip 
are not always accurate in predicting neuromuscular recovery and does not easily 
provide an objective evaluation of neuromuscular function. For example, a recent 
study found that 12% of patients who had good response to clinical tests were still at 
risk for residual block (Suy et al., 2007).  
 
One of the more accurate, quantitative and feasable methods to monitor depth 
of neuromuscular blockade is using the train-of-four (TOF) counts or ratio. This 
assesses return of function at neuromuscular junction prior to reversal. Although it is 
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not routinely used in daily anaesthetic practice, it is essential and beneficial in 
ensuring lower incidence of residual blockade or incomplete recovery post-reversal, 
which may be associated with debilitating side effects. Many anaesthesiologists still 
rely on clinical judgement and seldom use objective  monitoring of neuromuscular 
block. However, monitoring of neuromuscular function determines whether an 
antagonism of residual block is actually required and has been shown to be the only 
way to reduce the incidence of residual paralysis (Suy et al., 2007). 
 
Neostigmine, an anticholinesterase inhibitor has been widely used to reverse 
the effects of both aminosteroidal and benzylisoquinolone neuromuscular blocking 
agents since the 1970s. The use of acetylcholinesterase inhibitors for example 
neostigmine and endrophonium are associated with undesirable muscarinic side 
effects, which requires the use of a second drug in combination, which is an 
anticholinergic drug to counteract these side effects. In addition, there is a higher 
incidence of residual block in both adults and children. It is important to keep in 
mind that a recent study of upper airway dilator mucle activity and breathing showed 
that although the standard practice of reversal with cholinesterase inhibitors is 
relatively safe in patients who have residual block, but if these agents are given after 
complete spontaneous recovery, they can actually produce muscle weakness and 
possibly upper airway collapse (Eikermann et al., 2008).  
 
Sugammadex is a per-6-(2-carboxyethylthio)-per-6-deoxy-gamma-
cyclodextrin sodium salt. Su- refers to sugar and –gammadex refers to the structural 
molecule ƴ-cyclodextrin. It is the first and only selective relaxant-binding agent to be 
introduced in the market since 2008, and is now gaining popularity. It has been 
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designed to reverse the aminosteroidal neuromuscular blocking drug, (rocuronium, 
vecuronium, pancuronium from the most sensitive to least sensitive respectively) in 
the plasma, creating a concentration gradient favouring the movement of rocuronium 
molecules from the neuromuscular junction into the plasma. It encapsulates and 
deactivates the rocuronium molecule forming a tight, inclusion, stable, water-soluble 
complex at a 1;1 ratio, causing the rocuronium to no longer be available to freely 
bind to the nicotinic receptors at the neuromuscular junction. This promotes 
liberation of the acetylcholine receptors, and muscle activity reappears rapidly. 
Because of the low dissociation rate, no muscle weakness has been reported in 
available human or animal studies. 
 
The reversal of rocuronium induced neuromuscular blockade by sugammadex 
can be achieved using doses of 2mg/kg, 4mg/kg and 16mg/kg depending on the TOF 
readings. Studies have shown sugammadex achieves fast and efficient reversal of 
neuromuscular blockade, without the well-known undesirable cholinergic side effects 
associated with the use of cholinesterase inhibitors, such as bradycardia, 
hypersalivation, increased secretions, bronchoconstriction, abdominal cramps, 
nausea and vomiting. 
 
Paediatric patients differ from adult patients as the pharmacokinetic and 
pharmacodynamic profiles of neuromuscular blocking agents may vary according to 
age. For example, the clinical duration of rocuronium is prolonged in infants as 
compared to children, whereas the potency of rocuronium is higher in infants but 
lower in children as compared to adults. Studies have also shown that residual 
paralysis occurs more commonly in children as compared to adults. 
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This study therefore was carried out to compare the reversal of rocuronium 
induced neuromuscular blockade with the conventional reversal neostigmine and the 
newly introduced novel sugammadex in paediatric patients. Sugammadex has not 
been widely studied in paediatric patients, most studies with sample sizes of 24 
patients. A comparison study of the haemodynamic parametes and side effects also 
has yet to be done prior to this. 
 
To further understand this study, one would need adequate understanding 
regarding the neuromuscular physiology, the role of TOF monitoring and the 
pharmacokinetics and pharmacodynamics if each drug used.  
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CHAPTER 2 : LITERATURE REVIEW 
 
2.1  NEUROMUSCULAR PHYSIOLOGY 
The neuromuscular junction consists of a presynaptic nerve terminal, the 
synaptic cleft, and post-synaptic nicotinic receptors on the muscle membrane. An 
electrical impulse is transmitted along the motor nerve causing presynaptic 
acetylcholine release with binding of the neurotransmitter to the post-synaptic 
acetylcholine receptor. 
The presynaptic nerve terminal consists of the terminal part of the motor 
neurone which originates from the ventral horn of the spinal cord, losing its myelin 
as it nears the muscle fibre. Here, the Schwann cell anchors the nerve to the muscle 
membrane. Schwann cells play an important role in the maintenance of nerve 
homeostasis, providing stability and secreting growth and trophic factors, as well as 
axon development and synaptic formation. Schwann Cells control the number of 
neuromuscular junctions and remove superfluous presynaptic nerve terminals, 
especially during re-innervation, for instance, after crush injury. The presynaptic 
terminal also contains acetylcholine nicotinic receptors on the surface of the nerve 
membrane. Non-depolarizing and depolarizing neuromuscular blocking agents act on 
these receptors to mobilize acetylcholine, the former inhibit them and the latter 
stimulate them.. 
Acetylcholine is a neurotransmitter which is stored in vesicles. The release of 
acetylcholine on arrival of a nerve impulse results in sodium channel activation on 
the prejunctional nerve membrane. This in turn activates voltage-dependent calcium 
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channels (P-type fast channels) on the motor neurone causing an influx of calcium 
into the nerve cytoplasm that promotes further acetylcholine release. The calcium 
inflow is balanced by potassium ion outflow through potassium channels to maintain 
equilibrium across the nerve membrane. 
The post-junctional membrane consists of multiple folds with shoulders 
bearing the high-density clusters of acetylcholine, and clefts containing voltage-gated 
sodium channels. The high density ensures that acetylcholine elicits sufficient 
depolarization across the muscle membrane for muscle contraction.  
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Figure 2.1 The Neuromuscular Junction. Image adapted from http://www.frca.co.uk 
(Ackroyd and Gwinnutt, 2006) 
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2.2  ROCURONIUM 
 
2.2.1  Overview of Neuromuscular Blocking Agents 
 Neuromuscular blocking agents are frequently used during anaesthesia to 
facilitate tracheal intubation, artificial ventilation and to provide adequate relaxation 
for surgical procedures.   
There are many neuromuscular blocking agents currently used in daily 
practice of anaesthetists. These agents can be divided into depolarizing (for example 
succynylcholine) and non-depolarizing. Non depolaring muscle relaxants can be 
divided into 2 groups; aminosteroid (for example rocuronium, pancuronium, 
vecuronium) and benzylquinolones (for example atracurium, mivacurium, 
tubocurarine). 
Neuromuscular blocking agents also can be divided according to their 
duration of action. Short acting agents are succynylcholine and mivacurium, 
intermediate agents are atracurium, cisatracurium, vecuronium and rocuronium, long 
acting agents are pancuronium, pipecuronium and doxacurium. 
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2.2.2  Molecular structure 
 Rocuronium is a monoquartenary aminosteroid non-depolarizing 
neuromuscular blocking agent. It was introduced in 1994. Below is its chemical 
molecular structure: 
 
Figure 2.2 Rocuronium molecular structure. Image adapted from www.frca.co.uk 
(2007b) 
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2.2.3  Preparation 
 Rocuronium is a clear, colourless and odourless fluid prepared in a rubber 
sealed bottle. The preparation is 10mg/ml, available in 5ml and 10ml ampoules. It is 
mostly administered intravenously, but also can be administered intramuscularly. 
 
2.2.4  Mode of Action of Rocuronium 
 When administered, rocuronium molecules act at neuromuscular junctions of 
the skeletal muscle. It inhibits the action of acethylcholine (neurotransmitted) at the 
neuromuscular junction by competitively binding to the alpha subunit of the nicotinic 
acetylcholine receptor on the post-junctional membrane. This binding does not cause 
activation or change in configuration of the ion receptor channels, as would be 
typically seen in the binding of acetylcholine to the receptor. The action potential is 
therefore inhibited, as acetylcholine is unable to bind to the acetylcholine receptors. 
Neuromuscular transmission is blocked only after 80-90% of the receptors have been 
occupied by rocuronium molecules. 
 
2.2.5  Dosage, Onset and Duration of Action 
 Rocuronium has an ED95 of 0.3mg/kg. Intubating dose is 0.6mg/kg or 1-
1.2mg/kg (3-4 times ED95) for rapid sequence induction. Its onset of action is 
roughly 90 seconds. Its duration of action lasts 20-35 minutes.  
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2.2.6  Pharmacokinetics 
 Rocuronium is mostly excreted in the unchanged form (up to 50%) in 2 hours 
in the bile. Renal excretion of rocuronium is roughly 30% in 24 hours. Liver diseases 
increases its volume of distribution, therefore may prolong its duration of action. 
 
2.2.7  Side effects 
 Rocuronium is a fairly safe drug. It may cause minimal histamine release. It 
may also cause slight vagolytic effect. Patients may experience pain on injection 
(intravenous administration). There may be prolonged duration of action in patients 
with renal or liver impairment.   
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2.3  NEOSTIGMINE 
 
2.3.1  Overview of anticholinesterase drugs 
 Anticholinesterase drugs are most often administered by anaesthesiologist to 
improve and speed the recovery of neuromuscular function after neuromuscular 
blockade by non-depolarizing neuromuscular blocking agents. It can also be used to 
treat certain illness for example myasthenis gravis, glaucoma and to non-specificly 
antagonize the central nervous system effects of certain drugs for example urinary 
retention and constipation.  
Antichonisesterases can be classified according to its mechanism of action; 
easily reversible (endrophonium), formation of carbamylated enzyme complex 
(neostigmine, pyridostigmine, physostigmine) and irreversible inactivation by 
organophosphates. 
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2.3.2 Molecular structure 
 Neostigmine is a quartenary amine which is an ester of an alkyl carbamic acid. 
It has been used since the early 1930s. Its structure is as below : 
 
 
 
Figure 2.3 Neostigmine molecular structure. Image adapted from www.frca.co.uk 
(2010) 
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2.3.3  Preparation 
Neostigmine is available is tablets and in solution for intravenous injection. 
The intravenous form used widely in anaesthetic practice is clear, colorless and 
odourless in a 1ml ampoule. Its preparation is 2.5mg/ml. 
 
2.3.4  Mode of action 
Neostigmine functions by inhibiting the enzyme acetylcholinesterase, which 
hydrolyzes the neurotransmitter acetylcholine. Inhibition of this enzyme results in 
greater availability of acetylcholine at the sites of action, including preganglionic 
sympathetic and parasympathetic nerve ending in the neuromuscular junction. This 
enables more acetylcholine to competitively bind at the acetylcholine receptors of the 
neuromuscular junction. Therefore more miniature end plate potentials are produced, 
eventually producing an action potential. The increase in acetylcholine concentration 
also causes autonomic cholinergic effects like bradycardia and salivation, therefore it 
is often administered with an anticholinergic agent for example atropine or 
glycopyrrolate. 
 Neostigmoine produces reversible inhibition of acetylcholinesterase enzyme 
by forming a carbamyl ester complex at the esteratic site of the enzyme. Both 
acetylcholine and carbamate esters are hydrolysed by acetylcholisterterase enzymes. 
However acetylcholine acetylates the enzyme, while carbamate esters produce a 
carbamylated anzyme, which has a much slower rate of hydrolysis. This is also the 
reason why neostigmine is known as an acid transferring or time dependant 
acetylcholinesterase enzyme inhibitor. This carbamylated acetylcholinesterase cannot 
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hydrolyse acetylcholine until the carbamate-enzyme bond dissociates. Carbamylated 
acetylcholinesterase has a half-time of 15-30 minutes. 
 Neostigmine also inhibits plasma cholinesterases. 
 
2.3.5  Dosage, onset, duration of action 
 The dosage of neostigmine for reversal of neuromuscular blockade by non-
depolarizing muscle relaxants is 0.05mg/kg. In the treatment of myasthenia gravis, 
the dosage is 15-30mg orally. Its onset is intermediate, about 7-11 minutes, and 
duration of action is up to 1 hour. 
 
2.3.6  Pharmacokinetics 
 Neostigmine has a large volume of distribution 0.7litres/kg. Its elimination 
half time is 77 minutes. 50% is metabolized in the liver and 50% is cleared in the 
kidneys. Neostigmine has poor lipid solubility  
 
2.3.7  Side effects 
Neostigmine side effects are mainly parasympathetic, for example increased 
secretions, salivating, abdominal cramps, vomiting, bronchospasm and bradycardia. 
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2.4  SUGAMMADEX 
 
2.4.1  Introduction 
 Sugammadex is a modified gamma-cyclodextrin. It is the first selective 
relaxant binding agent to be introduced. It was previously known as Org 25969. It 
has a lipophilic core and hydrophilic 
 
2.4.2  Molecular structure 
 Sugammadex was introduced in 2008. The molecular structure is as below : 
 
 
 
 
 
 
 
 
 
Figure 2.4 Sugammadex molecular structure. Image adapted from 
www.chemicalbook.com(2007a) 
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Figure 2.5 Tri-dimensional structure of sugammadex (space-filling, ring shaped) 
Image adapted from Annals Of Cardiac Anaesthesia (Hemmerling et al., 2010) 
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2.4.3  Preparation 
 Sugammadex is prepared in a clear, colourless and odourless liquid, in a 
rubber-sealed ampoule. Its prepared in 100mg/ml. 
 
2.4.4  Mode of action 
 Sugammadex has a unique mode of action which differs from other reversal 
agents. It specifically encapsulates the aminosteroidal non-depolarizing 
neuromuscular blocking agent, rocuronium.  It has an inert doughnut shape. The 
eight side chain of sugammadex elongate the central cavity to ensure complete 
encapsulation of rocuronium, while the negatively charged carboxyl groups at the 
end of each chain enhances electrostatic binding to the positively charges nitrogen 
atom of rocuronium. This reduces the amount of rocuronium molecules readily 
available at the neuromuscular junction, allowing acetylcholine to occupy 
acetylcholine receptors to produce an action potential.  
 
2.4.5  Dosage, onset, duration of action 
 Sugammadex can be given in different doses, according to the degree of 
neuromuscular blockade. 2mg/kg is given for moderate blocks (at reappearance 
second twitch T2), 4mg/kg is given for deep blocks (TOF count less than 1, PTC 1 or 
2) and 16mg/kg is given for profound blocks (PTC 0) or for immediate reversal when 
rocuronium has just been administered. Its onset of action is 30-60 seconds. 
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2.4.6  Pharmacokinetics 
 Sugammadex has a volume of distribution of 0.2Litres/kg. It is not 
metabolized, but excreted unchanged in the kidneys. Elimination half life is 2.2 hours. 
 
2.4.7  Side effects 
 As of date, there is no clear known side effects of sugammadex. However, it 
is avoided or used with caution in patients with renal impairment.  There have been 
reports of possible prolongation of the QT interval of the electrocardiogram after 
sugammadex, and hypertension and hypotension have been reported after large doses 
(32 mg/kg). One report described accidental administration of a very large dose of 
sugammadex (40 mg kg−1), however, without any adverse effect on the 
cardiovascular system. 
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2.5  ROLE OF REVERSAL OF NEUROMUSCULAR BLOCK 
Reversal agents are administered at the end of surgery when muscle 
relaxation or neuromuscular paralysis is no longer desired. Reversal agents help 
accelerate the recovery of the neuromuscular function post-administration of a non-
depolarizing NMBA. The practice of administering neuromuscular blocking agents is 
very popular among anaesthetist worldwide, to avoid unwanted complications post-
extubation for example residual paralysis or recurarization, which may lead to 
debilitating effects. 
Residual paralysis poses a significant risk to a patient post-extubation.  The 
residual presence of volatile anaesthetic agents, benzodiazepines and narcotics in the 
tissue compartments contribute to this risk. Residual paralysis increases the risk of 
passive regurgitation of gastric contents because of pharyngeal and laryngeal muscle 
dysfunction, in spite of adequate diaphragm recovery. There is also evidence that 
NMBAs may interfere with hypoxic ventilatory control. The hypoxic ventilatory 
response is reduced by about 30% in awake volunteers when the TOF ratio is only 
0.7. The mechanism behind this interaction seems to be a reversible depression of 
carotid body chemoreceptor activity during hypoxia. This may potentiate 
postoperative brain injury. Postoperative pulmonary complications, especially 
atelectasis and pneumonia, are also associated with incomplete reversal. Atelectasis 
occurs during anaesthesia and is compounded in the postoperative period by any 
degree of residual paralysis (Srivastava and Hunter, 2009). 
Many studies have proven that patients who received NMBAs but no reversal 
agents experienced postoperative residual paralysis, whether in the aminosteroidal 
groups such as pancuronium, vecuronium and rocuronium or the benzylquinolones 
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group such as atracurium and cisatracurium. The incidence of residual curarization 
was much higher when infusions of NMBAs were used but no reversal agents were 
given. After a single dose of an intermediate-duration NMBA and no reversal, 
residual paralysis is common, even more than 2 hours after its administration. 
Recurarization is defined as an increase in neuromuscular block after a 
variable period of recovery. Recurarization was particularly common with the older 
NMBAs such as gallamine, d-tubocurarine and pancuronium. The problem was 
reduced with the introduction of atracurium and vecuronium. This is also contributed 
by improved neuromuscular monitoring. Recurarization may occur when a long-
acting NMBA is antagonized with an anticholinesterase that has a shorter duration of 
action. There may be an initial period of recovery from block, as acetylcholine 
concentrations increase as compared to NMBA concentrations post-administration of 
acetylcholinesterase inhibitors. As the anticholinesterase is redistributed and 
metabolized, its concentration falls at the NMJ, but the NMBA is still present. This 
effect is increased by respiratory acidosis and inadequate renal function, both of 
which potentiate the duration of effect of the older agents. 
Several techniques may be used to reduce the risk of postoperative residual 
paralysis, including avoidance of long-acting NMBAs, use of neuromuscular 
monitoring in the operating theatre, and reversal of block at a TOF count of at least 2.  
Ideally, any new reversal agent would have a more rapid onset of action, be 
efficacious irrespective of the degree of neuromuscular block, and have an improved 
side-effect profile. Only until recently, a selective relaxant binding agent 
sugammadex was introduced to the market, which fits these desirable criterias. 
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2.6  NEUROMUSCULAR MONITORING METHODS 
The anaesthetist can assess neuromuscular recovery muscle power by a 
variety of clinical tests, such as the ability to sustain head lift for 5 seconds or the 
ability to hold a tongue depressor between the teeth. These are a crude assessment of 
neuromuscular function, and can be influenced by many factors, for example, 
residual sedation or inability to follow instructions. In 1958, Christie and Churchill-
Davidson described the use of a nerve stimulator to monitor neuromuscular block. 
However, it was not until the TOF pattern of stimulation was described in 1970, that 
such equipment came into routine clinical use (McGrath and Hunter, 2006). 
 There are many methods of neuromuscular monitoring in anaesthesia. This is 
done using a device that delivers a desired magnitude and duration of electrical 
current (supramaximal stimuli) to stimulate a group of peripheral nerves to produce 
an action potential, whereby the associated muscular response is measured. 
Examples neuromuscular monitoring stimuli are Single Twitch stimulation, Tetanic 
stimulation, Double Burst Stimulation (DBS), Post-Tetanic Count (PTC) and Train 
Of Four (TOF) stimulation. 
Neuromuscular monitoring is an essential tool in anaesthetic practice, to 
ensure good neuromuscular recovery prior to extubation and to avoid undesired post-
operative adverse events. There is increasing evidence that residual neuromuscular 
block is common, and also that it may adversely affect patient outcome. 
 Although there is no evidence that residual neuromuscular block leads to 
increased mortality, significant pulmonary morbidity has been demonstrated after 
using longer-acting agents such as pancuronium. As well as interfering with 
pulmonary mechanics, residual neuromuscular block impairs the ventilatory response 
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to hypoxia. At low doses, these drugs significantly impair pharyngeal function and 
lead to an increased risk of tracheal aspiration and airway obstruction (McGrath and 
Hunter, 2006). 
When neuromuscular monitoring is used, visual or tactile evaluation of the 
degree of neuromuscular block is unreliable. Even experienced anaesthetists are 
unable to detect fade when the TOF ratio is >0.4. It is now thought that significant 
residual curarization is still present if the TOF ratio is <0.9 (not 0.7 as previously 
suggested). It is clear that as well as monitoring neuromuscular block clinically, we 
should be using quantitative techniques to assess the degree of recovery (McGrath 
and Hunter, 2006). 
 The following are basic principles regarding Single Twitch Stimulation, 
Tetanic Stimulation, Post-Tetanic Count and Double Burst Stimulation. Train Of 
Four Stimulation will be discussed under the TOF Watch Sx subheading. 
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2.6.1 Single Twitch Stimulation 
A single square wave supramaximal stimulus (0.1-1 Hertz) is applied to a 
peripheral nerve for a period of about 0.2 ms, at regular intervals (1-10 seconds), and 
the evoked response is observed. The twitch response will only be depressed when a 
neuromuscular blocking agent occupies 75% of the post-synaptic nicotinic receptors. 
Twitch depression will need to be more than 90% in order to provide good 
conditions for abdominal surgery. The most useful time to apply the single twitch 
pattern of nerve stimulation is at the onset of neuromuscular block. The onset and 
recovery from depolarizing and non-depolarizing block monitored using single 
twitches have a similar pattern, differing only in timescale. The major limitation to 
this technique is the need to measure a control twitch before administering the 
neuromuscular blocking agent.  
 
 
 
 
 
 
 
 
 
